Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical is poised for growth as they excel in the ADHD market and have a strong track record of successful mergers and acquisitions. With a focus on responsible pain management and a strong management team, the current stock price presents a potential investment opportunity. However, competition and market uncertainties make it difficult to have a fully positive outlook, leading to a Neutral rating and adjusted price target.

Bears say

Collegium Pharmaceutical is facing significant headwinds in its Pain franchise, with a looming revenue cliff in 2027 due to potential generic entry of Belbuca and Nucynta. The company's reliance on the continued success of its products in a highly competitive market, coupled with limited inorganic growth opportunities, presents risks to its long-term growth prospects. Furthermore, while the company has measures in place to mitigate the impact of potential generic competition, there is still uncertainty as to when and how this competition will manifest.

Collegium Pharmaceutical (COLL) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 7 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.